3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
300
Carcinoma, Non-Small-Cell Lung
80
Squamous Cell Carcinoma of Head and Neck
59
Carcinoma, Renal Cell
58
Neoplasms
40
Neoplasm Metastasis
36
Colorectal Neoplasms
36
Stomach Neoplasms
29
Carcinoma, Merkel Cell
29
Triple Negative Breast Neoplasms
28
Ovarian Neoplasms
28
Carcinoma, Transitional Cell
27
Uterine Cervical Neoplasms
24
Skin Neoplasms
24
Head and Neck Neoplasms
24
Lung Neoplasms
22
Breast Neoplasms
21
Carcinoma, Hepatocellular
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Esophageal Neoplasms
18
Pancreatic Neoplasms
16
Uveal Melanoma
14
Small Cell Lung Carcinoma
14
Sarcoma
14
Urinary Bladder Neoplasms
12
Lymphoma
11
Kidney Neoplasms
11
Endometrial Neoplasms
11
Brain Neoplasms
11
Prostatic Neoplasms
10
Interventions
Dermoscopy
2
pembrolizumab
1
Triamcinolone Acetonide
1
Tomography, Optical Coherence
1
Mechlorethamine
1
Interleukin-15
1
Diagnosis, Computer-Assisted
1
Control Groups
1
Bexarotene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
pembrolizumab
×
Dermatologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled